| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.44 | 0.01 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.01 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.086 | 0.02 |